AZ32

CAS No. ——

AZ32( —— )

Catalog No. M19313 CAS No. ——

AZ32 is an orally bioavailable and blood-brain barrier-penetrating ATM inhibitor with an IC50 of <6.2 nM for ATM enzyme, and an IC50 of 0.31 μM for ATM in cell.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 107 Get Quote
10MG 191 Get Quote
25MG 467 Get Quote
50MG 719 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    AZ32
  • Note
    Research use only, not for human use.
  • Brief Description
    AZ32 is an orally bioavailable and blood-brain barrier-penetrating ATM inhibitor with an IC50 of <6.2 nM for ATM enzyme, and an IC50 of 0.31 μM for ATM in cell.
  • Description
    AZ32 is an orally bioavailable and blood-brain barrier-penetrating ATM inhibitor with an IC50 of <6.2 nM for ATM enzyme, and an IC50 of 0.31 μM for ATM in cell.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    ERK
  • Recptor
    ATM|ATM (in cell)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    328.37
  • Molecular Formula
    C20H16N4O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CNC(=O)c1ccc(cc1)c2cnc3cnc(cn23)c4ccccc4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Karlin J, et al. Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice. Mol Cancer Ther. 2018 Aug;17(8):1637-1647.
molnova catalog
related products
  • CC-90003

    CC-90003 (CC90003) is a potent and selective, covalent ERK1/2 inhibitor with IC50 of 10-20 nM.

  • Byakangelicol

    Byakangelicol may inhibit P-gp expressed at the BBB even under in vivo conditions.

  • AZD0364

    AZD0364 (AZD-0364) is a potent, selective, orally active ERK1/2 inhibitor for treatment of NSCLC.